(Q34787689)

4 August 2017

1 reference

title

Design and selection of vaccine adjuvants: animal models and human trials (English)

1 reference

4 August 2017

1 reference

1 reference

Carl R Alving

1

1 reference

PubMed ID

12184368

4 August 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

4 August 2017

1 reference

4 August 2017

20 Suppl 3

1 reference

4 August 2017

S56-64

1 reference

Summary: Adjuvants/Clinical Trials Working Group

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

1 reference

7 January 2021

Adjuvants--a classification and review of their modes of action

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Immunological concepts of vaccine adjuvant activity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Adjuvants for human vaccines--current status, problems and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Adjuvants for anti-parasite vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Adjuvants--a balance between toxicity and adjuvanticity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Immunological adjuvants: a role for liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Liposomes as carriers of antigens and adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Liposomes and ISCOMS as vaccine formulations.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Cytokines as immunological adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Cytokines as potential vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

1 reference

7 January 2021

Structural requirements of lipid A for endotoxicity and other biological activities

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

The use of adjuvants in studies on influenza immunization. I. Measurements in monkeys of the dimensions of antigenicity of virus-mineral oil emulsions

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Use of adjuvants in studies on influenza immunization. III. Degree of persistence of antibody in human subjects two years after vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Use of poliomyelitis virus vaccine in light mineral oil adjuvant in a community immunization program and report of reactions encountered

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

FOLLOW-UP STUDY ON ARMY PERSONNEL WHO RECEIVED ADJUVANT INFLUENZA VIRUS VACCINE 1951-1953

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine in 1951-1953.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Percutaneous exposure of adjuvant oil causes arthritis in DA rats

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Prospects for control of herpes simplex virus disease through immunization.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Why do we lack an effective vaccine against herpes simplex virus infections?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Genital Herpes in Guinea Pigs: Pathogenesis of the Primary Infection and Description of Recurrent Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

The role of adjuvants in retroviral vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Use of novel adjuvants and delivery systems to improve the humoral and cellular immune response to malaria vaccine candidate antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Altered in vivo activity of liposome-incorporated lipopolysaccharide and lipid A.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Selection of potent immunological adjuvants for vaccine construction

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900174-3

7 January 2021

10.1016/S0264-410X(02)00174-3

Identifiers

DOI

1 reference

release_zykprnlgizggfbkqzq6iroo4bu

4 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zykprnlgizggfbkqzq6iroo4bu

24 November 2022

mapped directly with Wikidata item

PubMed ID

12184368

1 reference

PubMed ID

12184368